Lisata Therapeutics (LSTA) Q1 2025 earnings summary

Executive summary

• Advanced certepetide clinical portfolio with strong early results, including positive ASCEND Cohort A data and multiple ongoing Phase 2 trials in solid tumors such as pancreatic, cholangiocarcinoma, colon, appendiceal cancer, and glioblastoma.

• Maintained momentum into 2025 despite market headwinds for small-cap healthcare companies, supported by a seasoned management team and global IP protection through 2040.

• Multiple collaborations and licensing agreements established, including with Qilu Pharmaceutical, Valo Therapeutics, Kuva Labs, and Catalent, expanding certepetide's applications and reach.

• Certepetide received FDA Fast Track and Orphan Drug designations for several indications, and a Rare Pediatric Disease designation for osteosarcoma.

• Cash runway extends into Q3 2026 with no debt, supporting ongoing and planned clinical programs.

Financial highlights

• Operating expenses for Q1 2025 were $5.8 million, down 11.4% from $6.6 million in Q1 2024; R&D expenses decreased 19.7% to $2.6 million, and G&A expenses fell 3.4% to $3.2 million.

• Net loss for Q1 2025 was $4.7 million, compared to $5.4 million in Q1 2024.

• Cash, cash equivalents, and marketable securities totaled $25.8 million as of March 31, 2025.

• 8.6 million common shares outstanding, 1.5 million options, and 1.5 million warrants as of March 31, 2025.

• Benefit from income taxes of $1.0 million recognized from sale of New Jersey NOLs; $0.1 million loss on sale recorded in other income.

Outlook and guidance

• Cash position expected to fund operations into Q3 2026, covering planned milestones and clinical programs.

• Anticipates a data-rich 12–18 months with key clinical trial readouts, including final ASCEND Cohort B data by mid-2025 and multiple other trial results.

• Focused on initiating only trials that can be funded with existing or guaranteed capital, with short-term capital needs managed by delaying certain activities.